대한치매학회지 (Dementia and Neurocognitive Disorders)

대한치매학회 (Korean Dementia Association)
권호 표지
DOI QR코드

DOI QR Code

Revolutionizing Alzheimer's Diagnosis and Management: The Dawn of Biomarker-Based Precision Medicine

  • Hyuk Sung Kwon (Department of Neurology, Hanyang University College of Medicine) ;
  • Hyun-Jung Yu (Department of Neurology, Bundang Jesaeng General Hospital) ;
  • Seong-Ho Koh (Department of Neurology, Hanyang University College of Medicine)
  • 투고 : 2024.09.05
  • 심사 : 2024.10.16
  • 발행 : 2024.10.31
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Alzheimer's disease (AD), a leading cause of dementia, presents a formidable global health challenge intensified by the aging population. This review encapsulates the evolving landscape of AD diagnosis and treatment with a special focus on the innovative role of fluid biomarkers. Pathologically, AD is marked by amyloid beta (Aβ) plaques and neurofibrillary tangles of hyperphosphorylated tau, which lead to synaptic dysfunction, neuronal loss, and cognitive decline. These pathological changes, commencing decades before symptom onset, underscore the need for early detection and intervention. Diagnosis traditionally relies on clinical assessment, neuropsychological testing, and neuroimaging techniques. However, fluid biomarkers in cerebrospinal fluid and blood, such as various forms of Aβ, total tau, phosphorylated tau, and neurofilament light chain, are emerging as less invasive, cost-effective diagnostic tools. These biomarkers are pivotal for early diagnosis, differential diagnosis, disease progression monitoring, and treatment response evaluation. The treatment landscape is shifting toward personalized medicine, highlighted by advancements in Aβ immunotherapies, such as lecanemab and donanemab. Demonstrating efficacy in phase III clinical trials, these therapies hold promise as tailored treatment strategies based on individual biomarker profiles. The integration of fluid biomarkers into clinical practice represents a significant advance in AD management, providing the potential for early and precise diagnosis, coupled with personalized therapeutic approaches. This heralds a new era in combating this debilitating disease.

키워드

과제정보

This work was supported by grants from the Korea Health Technology R&D Project through the Korea Health Industry Development Institute, funded by the Ministry of Health & Welfare, Republic of Korea (RS-2021-KH112011), and the Basic Science Research Program through the National Research Foundation of Korea (grant number: RS-2022-00165945, RS-2023-00278819 and RS-2024-00431471).

참고문헌

  1. 2022 Alzheimer's disease facts and figures. Alzheimers Dement 2022;18:700-789.
  2. GBD 2019 Dementia Forecasting Collaborators. Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050: an analysis for the Global Burden of Disease Study 2019. Lancet Public Health 2022;7:e105-e125.
  3. Prince MJ, Wimo A, Guerchet MM, Ali GC, Wu YT, Prina M. World Alzheimer Report 2015 - The Global Impact of Dementia: An Analysis of Prevalence, Incidence, Cost and Trends. London: Alzheimer's Disease International; 2015.
  4. Shin JH. Dementia epidemiology fact sheet 2022. Ann Rehabil Med 2022;46:53-59.
  5. Shon C, Yoon H. Health-economic burden of dementia in South Korea. BMC Geriatr 2021;21:549.
  6. Long JM, Holtzman DM. Alzheimer disease: an update on pathobiology and treatment strategies. Cell 2019;179:312-339.
  7. Scheltens P, De Strooper B, Kivipelto M, Holstege H, Chetelat G, Teunissen CE, et al. Alzheimer's disease. Lancet 2021;397:1577-1590.
  8. Kwon HS, Koh SH. Neuroinflammation in neurodegenerative disorders: the roles of microglia and astrocytes. Transl Neurodegener 2020;9:42.
  9. Selkoe DJ, Hardy J. The amyloid hypothesis of Alzheimer's disease at 25 years. EMBO Mol Med 2016;8:595-608.
  10. DeTure MA, Dickson DW. The neuropathological diagnosis of Alzheimer's disease. Mol Neurodegener 2019;14:32.
  11. Hanseeuw BJ, Betensky RA, Jacobs HI, Schultz AP, Sepulcre J, Becker JA, et al. Association of amyloid and tau with cognition in preclinical Alzheimer disease: a longitudinal study. JAMA Neurol 2019;76:915-924.
  12. Aisen PS, Cummings J, Jack CR Jr, Morris JC, Sperling R, Frolich L, et al. On the path to 2025: understanding the Alzheimer's disease continuum. Alzheimers Res Ther 2017;9:60.
  13. Kim SH, Noh MY, Kim HJ, Oh KW, Park J, Lee S, et al.; K-ARPI. A therapeutic strategy for Alzheimer's disease focused on immune-inflammatory modulation. Dement Neurocogn Disord 2019;18:33-46.
  14. van Dyck CH, Swanson CJ, Aisen P, Bateman RJ, Chen C, Gee M, et al. Lecanemab in early Alzheimer's disease. N Engl J Med 2023;388:9-21.
  15. Sims JR, Zimmer JA, Evans CD, Lu M, Ardayfio P, Sparks J, et al. Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial. JAMA 2023;330:512-527.
  16. Cummings J, Zhou Y, Lee G, Zhong K, Fonseca J, Cheng F. Alzheimer's disease drug development pipeline: 2024. Alzheimers Dement 2024;10:e12465.
  17. Lennon MJ, Rigney G, Raymont V, Sachdev P. Genetic therapies for Alzheimer's disease: a scoping review. J Alzheimers Dis 2021;84:491-504.
  18. Stepanichev M. Gene editing and Alzheimer's disease: is there light at the end of the tunnel? Front Genome Ed 2020;2:4.
  19. Cao Y, Zhang R. The application of nanotechnology in treatment of Alzheimer's disease. Front Bioeng Biotechnol 2022;10:1042986.
  20. Mir Najib Ullah SN, Afzal O, Altamimi AS, Ather H, Sultana S, Almalki WH, et al. Nanomedicine in the management of Alzheimer's disease: state-of-the-art. Biomedicines 2023;11:1752.
  21. Ward A, Tardiff S, Dye C, Arrighi HM. Rate of conversion from prodromal Alzheimer's disease to Alzheimer's dementia: a systematic review of the literature. Dement Geriatr Cogn Dis Extra 2013;3:320-332.
  22. Young PN, Estarellas M, Coomans E, Srikrishna M, Beaumont H, Maass A, et al. Imaging biomarkers in neurodegeneration: current and future practices. Alzheimers Res Ther 2020;12:49.
  23. Jack CR Jr, Knopman DS, Jagust WJ, Shaw LM, Aisen PS, Weiner MW, et al. Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol 2010;9:119-128.
  24. Jack CR Jr, Bennett DA, Blennow K, Carrillo MC, Dunn B, Haeberlein SB, et al.; Contributors. NIAAA Research Framework: toward a biological definition of Alzheimer's disease. Alzheimers Dement 2018;14:535-562.
  25. Jack CR Jr, Andrews JS, Beach TG, Buracchio T, Dunn B, Graf A, et al. Revised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer's Association Workgroup. Alzheimers Dement 2024;20:5143-5169.
  26. Chang M. Roche diagnostics wins nod for Alzheimer's disease CSF test in Korea [Internet]. Seoul: Korea Biomedical Review; 2023 [cited 2024 Sep 5]. https://www.koreabiomed.com/news/articleView.html?idxno=21685.
  27. Park SA, Jang YJ, Kim MK, Lee SM, Moon SY. Promising blood biomarkers for clinical use in Alzheimer's disease: a focused update. J Clin Neurol 2022;18:401-409.
  28. McGrowder DA, Miller F, Vaz K, Nwokocha C, Wilson-Clarke C, Anderson-Cross M, et al. Cerebrospinal fluid biomarkers of Alzheimer's disease: Current evidence and future perspectives. Brain Sci 2021;11:215.
  29. Zetterberg H, Schott JM. Blood biomarkers for Alzheimer's disease and related disorders. Acta Neurol Scand 2022;146:51-55.
  30. Hansson O, Blennow K, Zetterberg H, Dage J. Blood biomarkers for Alzheimer's disease in clinical practice and trials. Nat Aging 2023;3:506-519.
  31. Park SH, Lee EH, Kim HJ, Jo S, Lee S, Seo SW, et al. The relationship of soluble TREM2 to other biomarkers of sporadic Alzheimer's disease. Sci Rep 2021;11:13050.
  32. Brand AL, Lawler PE, Bollinger JG, Li Y, Schindler SE, Li M, et al. The performance of plasma amyloid beta measurements in identifying amyloid plaques in Alzheimer's disease: a literature review. Alzheimers Res Ther 2022;14:195.
  33. Thijssen EH, La Joie R, Wolf A, Strom A, Wang P, Iaccarino L, et al. Diagnostic value of plasma phosphorylated tau181 in Alzheimer's disease and frontotemporal lobar degeneration. Nat Med 2020;26:387-397.
  34. Suarez-Calvet M, Karikari TK, Ashton NJ, Lantero Rodriguez J, Mila-Aloma M, Gispert JD, et al. Novel tau biomarkers phosphorylated at T181, T217 or T231 rise in the initial stages of the preclinical Alzheimer's continuum when only subtle changes in Aβ pathology are detected. EMBO Mol Med 2020;12:e12921.
  35. Cai H, Pang Y, Fu X, Ren Z, Jia L. Plasma biomarkers predict Alzheimer's disease before clinical onset in Chinese cohorts. Nat Commun 2023;14:6747.
  36. Meyer PF, Ashton NJ, Karikari TK, Strikwerda-Brown C, Kobe T, Gonneaud J, et al. Plasma p-tau231, p-tau181, PET biomarkers, and cognitive change in older adults. Ann Neurol 2022;91:548-560.
  37. Palmqvist S, Tideman P, Cullen N, Zetterberg H, Blennow K, Dage JL, et al. Prediction of future Alzheimer's disease dementia using plasma phospho-tau combined with other accessible measures. Nat Med 2021;27:1034-1042.
  38. Therriault J, Servaes S, Tissot C, Rahmouni N, Ashton NJ, Benedet AL, et al. Equivalence of plasma p-tau217 with cerebrospinal fluid in the diagnosis of Alzheimer's disease. Alzheimers Dement 2023;19:4967-4977.
  39. Ashton NJ, Brum WS, Di Molfetta G, Benedet AL, Arslan B, Jonaitis E, et al. Diagnostic accuracy of a plasma phosphorylated tau 217 immunoassay for Alzheimer disease pathology. JAMA Neurol 2024;81:255-263.
  40. Kwon HS, Lee EH, Kim HJ, Park SH, Park HH, Jeong JH, et al. Predicting amyloid PET positivity using plasma p-tau181 and other blood-based biomarkers. Alzheimers Dement (Amst) 2023;15:e12502.
  41. Kwon HS, Kim JY, Koh SH, Choi SH, Lee EH, Jeong JH, et al. Predicting cognitive stage transition using p-tau181, Centiloid, and other measures. Alzheimers Dement 2023;19:4641-4650.
  42. Bellaver B, Povala G, Ferreira PC, Ferrari-Souza JP, Leffa DT, Lussier FZ, et al. Astrocyte reactivity influences amyloid-β effects on tau pathology in preclinical Alzheimer's disease. Nat Med 2023;29:1775-1781.
  43. Jin M, Cao L, Dai YP. Role of neurofilament light chain as a potential biomarker for Alzheimer's disease: a correlative meta-analysis. Front Aging Neurosci 2019;11:254.
  44. Gaetani L, Blennow K, Calabresi P, Di Filippo M, Parnetti L, Zetterberg H. Neurofilament light chain as a biomarker in neurological disorders. J Neurol Neurosurg Psychiatry 2019;90:870-881.
  45. Lee EH, Kwon HS, Koh SH, Choi SH, Jin JH, Jeong JH, et al. Serum neurofilament light chain level as a predictor of cognitive stage transition. Alzheimers Res Ther 2022;14:6.
  46. Guerreiro R, Wojtas A, Bras J, Carrasquillo M, Rogaeva E, Majounie E, et al. TREM2 variants in Alzheimer's disease. N Engl J Med 2013;368:117-127.
  47. Jonsson T, Stefansson H, Steinberg S, Jonsdottir I, Jonsson PV, Snaedal J, et al. Variant of TREM2 associated with the risk of Alzheimer's disease. N Engl J Med 2013;368:107-116.
  48. Ashton NJ, Suarez-Calvet M, Heslegrave A, Hye A, Razquin C, Pastor P, et al. Plasma levels of soluble TREM2 and neurofilament light chain in TREM2 rare variant carriers. Alzheimers Res Ther 2019;11:94.
  49. Guo Y, Huang YY, Shen XN, Chen SD, Hu H, Wang ZT, et al. Characterization of Alzheimer's tau biomarker discordance using plasma, CSF, and PET. Alzheimers Res Ther 2021;13:93.
  50. Angioni D, Hansson O, Bateman RJ, Rabe C, Toloue M, Braunstein JB, et al. Can we use blood biomarkers as entry criteria and for monitoring drug treatment effects in clinical trials? A report from the EU/US CTAD task force. J Prev Alzheimers Dis 2023;10:418-425. PUBMED
  51. Kwon HS, Koh SH. Monitoring patients with dementia: Insight into global trends, innovations, and future directions. J Clin Neurol 2024;20:239-240.